Agilux’s unique combination of early-stage services, coupled with our existing discovery and safety assessment capabilities, will greatly enhance the speed and efficiency of your lead identification, optimization and candidate selection.
Our latest paper, featured on the cover of ASSAY and Drug Development Technologies, discusses the development and validation of high-throughput screens for human nicotinic receptor subtypes in automated patch-clamp.
Charles River is now able to offer CTLA4 and PD-1/PD-L1 reporter bioassays, along with a bioassay for human growth hormone (HGH).
Our partnership with PathoQuest will now provide an NGS-based testing solution, which can identify viral contaminants in biological products via a single comprehensive test.
Charles River offers a full spectrum of ready-to-use analytical methods for the detection and quantification of process- and product-related residuals and impurities.
New PCR and serology assays including Zika, Dengue and West Nile virus are now available for screening nonhuman primate colonies.
High-throughput mass spectrometry enables high-quality data from very large-scale screens to ID hits for difficult targets.
Humanized models help simulate the immune environment needed to investigate new immuno-oncology therapies.
We are pleased to announce our newly designed Gnoto-safe® Shipping (GSS) container, which combines the latest in animal welfare and colony management in an environmentally responsible way. Beginning Sunday, September 4, 2016, all VAF/Elite® and immunodeficient animal models ordered through Charles River will be shipped to you in this new container.
Charles River has established ICH core battery tests and supplementary safety pharmacology models to meet current regulatory requirements. In an effort to further support our partners' needs, Charles River is continually validating state-of-the-art equipment, assays and experimental techniques to improve both current evaluations and animal welfare.